HealthEquityFRA:2HE -0.61%93 PS Ratio is 6.16 as of Jul. 12, 2026, which is 14% below its 10-year median of 7.20. GuruFocus rates FRA:2HE with a GF Score™ of 93/100 and a GF Value™ of €89.27. The stock has 2 warning signs investors should review. Among 659 Healthcare Providers & Services companies, HealthEquity ranks worse than 83.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, HealthEquity's share price is €81.50.
HealthEquity's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was €13.22. Hence, HealthEquity's PS Ratio for today is 6.16.
The historical rank and industry rank for HealthEquity's PS Ratio or its related term are showing as below:
FRA:2HE'
s PS Ratio Range Over the Past 10 Years
Min: 4.46 Med: 7.2 Max: 23.54
Current: 6.11
During the past 13 years, HealthEquity's highest PS Ratio was 23.54. The lowest was 4.46. And the median was 7.20.
FRA:2HE's PS Ratio is ranked worse than 83.92% of 659
companies
in the Healthcare Providers & Services industry
Industry Median: 1.48
vs FRA:2HE: 6.11
HealthEquity Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of HealthEquity was 10.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 21.00% per year.
During the past 13 years, HealthEquity's highest 3-Year average Revenue per Share Growth Rate was 37.70% per year. The lowest was -35.30% per year. And the median was 26.20% per year.
Back to Basics: PS Ratio
HealthEquity (FRA:2HE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
HealthEquity PS Ratio Related Terms
HealthEquity PS Ratio Historical Data
* Premium members only.
The historical data trend for HealthEquity's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, HealthEquity's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthEquity PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthEquity's PS Ratio distribution charts can be found below:
* The bar in red indicates where HealthEquity's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
HealthEquity's PS Ratio for today is calculated as
HealthEquity's Share Price of today is €81.50. HealthEquity's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
HealthEquity (FRA:2HE) has a PS Ratio of 6.16 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on HealthEquity and its competitors. This is 14% below median its historical median of 7.20. Over the past decade, HealthEquity's PS Ratio has ranged from 4.46 to 23.54. According to the industry distribution chart, HealthEquity ranks #553 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 83.9%.
Is HealthEquity's PS Ratio too high?
HealthEquity's current PS Ratio of 6.16 is 14% below median its 10-year median of 7.20. Over the past 10 years, this metric has ranged from a low of 4.46 to a high of 23.54. The Healthcare Providers & Services industry median PS Ratio is 1.48. HealthEquity's value of 6.16 is 316.2% above this industry median. Based on the distribution chart, HealthEquity ranks #553 out of 659 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, HealthEquity has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's PS Ratio compare to HNGE and TEM?
According to the Healthcare Providers & Services industry distribution chart, HealthEquity ranks #553 out of 659 companies for PS Ratio. This places HealthEquity in the lower half of its industry. The industry median PS Ratio is 1.48. HealthEquity's value of 6.16 is 316.2% above this benchmark. Historically, HealthEquity's own PS Ratio has ranged from 4.46 to 23.54 over the past decade. While the company's 10-year median is 7.20 vs. the industry median of 1.48, HealthEquity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.48, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HealthEquity's current PS Ratio of 6.16 is 316.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on HealthEquity and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HealthEquity's current PS Ratio is 6.16, which is 14% below median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
HealthEquity (FRA:2HE) has a current PS Ratio of 6.16. The stock's GF Value™ is €89.27, compared to a current price of €81.50 — trading 8.7% below its estimated fair value. The current PS Ratio is 6.16, which is 14% below median its 10-year median of 7.20 and 316.2% above the Healthcare Providers & Services industry median of 1.48. HealthEquity's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current PS Ratio is 6.16 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthEquity (FRA:2HE) Overvalued in 2026?
Based on GuruFocus' analysis, HealthEquity stock appears to be undervalued.
The current stock price of €81.50 is trading 8.7% below its estimated GF Value™ of €89.27.
Key valuation signals for FRA:2HE:
PS Ratio: 6.16 (14% below median its 10-year median of 7.20)
GF Value™: €89.27 vs. price of €81.50 (8.7% below fair value)
Industry Position: 316.2% above the Healthcare Providers & Services median (#553 of 659)
No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
93GF Score
Get the complete analysis for FRA:2HE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2HE has been successfully added to your 
